Page 10 - இஸ்ரேலி கண்டுபிடிப்பு அதிகாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FemTech startup OCON Healthcare completes funding round and appoints Dr Anula Jayasuriya to Chairwoman

, a women s health company which develops, manufactures and commercializes innovative 3D intrauterine devices based on its patented IUB™ (Intra-Uterine Ball) platform, announced that it has completed a USA-focused funding round led by Rhia Ventures, to bring its IUB Ballerine® contraceptive and IUB SEAD™ point-of-care therapy for Abnormal Uterine Bleeding (AUB), to the US market, and to expand Phase II clinical trials for the IUB SEAD™. OCON Healthcare completes funding round towards US market. OCON’s IUB Ballerine® is the first ever 3D spherical copper intrauterine contraceptive with a superior safety profile OCON also appointment California-based Dr. Anula Jayasuriya to Chairwoman, an accomplished private equity and VC leader with over 30 years of business, scientific and medical expertise. I m excited to be appointed chairwoman of the OCON board, said

Israel generalRavit levrannKeren leshemStasia obremskeyIsraeli innovation authorityIntra uterine ballUnited states focusedRhia venturesAbnormal uterine bleedingAnula jayasuriyaAstia angelsIsraeli innovationManaging directorRhia ventureஇஸ்ரேல் ஜநரல்கர்ரந் லேஷெம்

Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority

Press release content from Business Wire. The AP news staff was not involved in its creation. Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority December 18, 2020 GMT SAN FRANCISCO & NESS ZIONA, Israel (BUSINESS WIRE) Dec 18, 2020 Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech innovation hub in Israel and is Atomwise’s second partnership with a global incubator hub.

United statesJuergen eckhardtAtomwise atomnetSara agee leHansoh pharmaAnya eldanKinneret savitzkyTakeda ventures incIsraeli innovation authorityInnovation authorityHead of startup divisionJohnson innovation jjdc incTakeda pharmaceutical companyJohnson innovationOrbimed israel partnersChief executive officer

Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority

(1) A2i Therapeutics secures seed funding from FutuRx and its investors Johnson Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority to develop novel small molecule immuno-oncology agents. Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise s AtomNet platform for AI-based drug discovery to a growing biotech innovation hub in Israel and is Atomwise s second partnership with a global incubator hub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201218005044/en/

Juergen eckhardtAtomwise atomnetKostenloser wertpapierhandelSara agee leHansoh pharmaAnya eldanKinneret savitzkyTakeda ventures incIsraeli innovation authorityInnovation authorityHead of startup divisionJohnson innovation jjdc incTakeda pharmaceutical companyJohnson innovationTakeda venturesOrbimed partners

Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority - Press Release

Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority - Press Release
digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.

Juergen eckhardtAtomwise atomnetHansoh pharmaAnya eldanKinneret savitzkyTakeda ventures incIsraeli innovation authorityInnovation authorityHead of startup divisionJohnson innovation jjdc incTakeda pharmaceutical companyBusiness wireJohnson innovationOrbimed israel partnersChief executive officerIsraeli innovation

Atomwise and FutuRx Launch A2i Therapeutics – A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority – IT Business Net

Atomwise and FutuRx Launch A2i Therapeutics – A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Juergen eckhardtAtomwise atomnetHansoh pharmaAnya eldanKinneret savitzkyTakeda ventures incIsraeli innovation authorityInnovation authorityHead of startup divisionJohnson innovation jjdc incTakeda pharmaceutical companyJohnson innovationTakeda venturesOrbimed partnersOrbimed israel partnersChief executive officer